UniQure NV - Company Profile
Powered by 
All the sales intelligence you need on UniQure NV in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how UniQure NV fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with UniQure NV.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
UniQure NV (UniQure) is a biotechnology company that researches, develops, and commercializes gene therapies for rare and severe diseases using an adeno-associated virus (AAV)-based technology platform. The company's pipeline of innovative gene therapies focuses on the treatment of Huntington’s disease, amyotrophic lateral sclerosis (ALS) caused by mutations in superoxide dismutase 1 (SOD 1), refractory mesial temporal lobe epilepsy (mTLE), and Fabry disease. UniQure’s lead product, AMT-060, is a gene therapy for the treatment of moderately-severe hemophilia B. The company, which distributes etranacogene dezaparvovec, is used to treat Hemophilia B. Its preclinical products include AMT-130, which focuses on the treatment of Huntington disease; AMT-260, to treat Temporal Lobe Epilepsy; AMT-191, to treat Fabry disease; and AMT-162, to treat ALS (SOD1). It has operations in the US, the Netherlands, and Switzerland. UniQure is headquartered in Amsterdam, the Netherlands.
Headquarters
Netherlands
Address
Paasheuvelweg 25a, Amsterdam, Noord-Holland, 1105BP
Website
www.uniqure.com
Telephone
31 202 406000
No of Employees
209
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
QURE (NASD)
Revenue (2024)
$16.1M
-40.6%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
16.9%
(2024 vs 2023)
Market Cap*
$1.6B
Net Profit Margin (2024)
XYZ
-39.9%
(2024 vs 2023)
* As of and is in US$
UniQure NV premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Etranacogene Dezaparvovec: Hemophilia B | miQURE |
| AMT-130: Huntington’s Disease | GoQURE |
| AMT-260: Temporal Lobe Epilepsy | LinQURE |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In April, the company announced that the US Food and Drug Administration (FDA) had granted breakthrough therapy designation to AMT-130 for the treatment of Huntington’s disease. |
| 2024 | Contracts/Agreements | In December, the company signed an agreement with the U.S. Food and Drug Administration for an Accelerated Approval pathway for AMT-130. |
| 2024 | Regulatory Approval | In September, the company announced orphan drug designation had been granted to AMT-191 for the treatment of Fabry disease by the US FDA. |
Competitor Comparison
| Key Parameters | UniQure NV | Roche Holding AG | Pfizer Inc | Sanofi | Takeda Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Netherlands | Switzerland | United States of America | France | Japan |
| City | Amsterdam | Basel | New York City | Paris | Chuo-Ku |
| State/Province | Noord-Holland | Basel-Stadt | New York | Ile-de-France | Tokyo |
| No. of Employees | 209 | 112,774 | 75,000 | 76,493 | 47,455 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Matthew Kapusta | Chief Executive Officer; Director | Executive Board | 2016 | 52 |
| Christian Klemt | Chief Financial Officer | Senior Management | 2021 | 52 |
| Walid Abi-Saab, MD | Chief Medical Officer | Senior Management | 2023 | 59 |
| Richard Porter | Chief Business Officer; Chief Scientific Officer | Senior Management | 2023 | - |
| Amin Abujoub, PhD | Chief Technical Operations Office | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer